More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...

July 10, 2024 — Scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus ... May 23, 2024 — Treatment of autoimmune diseases ...

Objective Disease activity both between and within patients with SLE is highly variable, yet factors driving this variability remain unclear. This study aimed to identify predictors of variability in ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

SOUTH SAN FRANCISCO, Calif. - Alumis Inc. (NASDAQ: ALMS), currently valued at $388 million and trading near its 52-week low of $6.29, and ACELYRIN, INC. (NASDAQ: SLRN) have entered into a definitive ...

A sun rash is an immune system reaction to sunlight exposure that causes itchy bumps, raised patches, or blisters on your ...

A 2021 review of 17 studies involving 1,326 participants (635 with lupus and 691 without) found that 27% of individuals with systemic lupus erythematosus ... of sound). Treatment options for ...

had active SLE disease and have been on stable SLE treatment regimen. Lupus activity was defined by presence of SS score of at least 4. Some of the exclusions were patients treated with ...

Lifestyle strategies and closely following treatment may help decrease the chance of this happening. Hypoglycemia is a possible but uncommon symptom of systemic forms of lupus, like SLE.

An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of B-cell mediated autoimmune diseases, including systemic lupus erythematosus ...